Media stories about Shire (NASDAQ:SHPG) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Shire earned a news impact score of 0.20 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.9662601968132 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

SHPG has been the topic of a number of research reports. ValuEngine upgraded shares of Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. Stifel Nicolaus restated a “buy” rating and set a $245.00 target price on shares of Shire in a research report on Sunday, October 8th. Royal Bank of Canada restated a “buy” rating and set a $213.00 target price on shares of Shire in a research report on Monday, October 2nd. FBR & Co initiated coverage on shares of Shire in a research report on Thursday, October 19th. They set a “buy” rating and a $201.00 target price on the stock. Finally, Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the company a “buy” rating in a research report on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $212.18.

Shares of Shire (SHPG) traded down $1.59 during trading hours on Tuesday, hitting $145.96. 2,141,855 shares of the company were exchanged, compared to its average volume of 1,202,044. The firm has a market cap of $44,384.22, a P/E ratio of 27.33, a price-to-earnings-growth ratio of 0.79 and a beta of 1.60. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire has a 1-year low of $137.17 and a 1-year high of $192.15.

Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.64 by $0.17. The business had revenue of $3.70 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The business’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.17 earnings per share. equities analysts anticipate that Shire will post 15 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/16/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-shire-shpg-share-price.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Insider Buying and Selling by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.